Article
Development of novel quality control material based on CRISPR/Cas9 editing and xenografts for MLH1 protein deficiency testing.
Journal of clinical laboratory analysis - 1 May 2021
Li Rui, Zhang Runling, Tan Ping, Wang Meng, Chen Yuqing, Zhang Jiawei, Han Dongsheng, Han Yanxi, Li Jinming, Zhang Rui
Abstract excerpt
BACKGROUND: Mismatch repair deficiency (dMMR) status induced by MLH1 protein deficiency plays a pivotal role in therapeutic decision-making for cancer patients. Appropriate quality control (QC) materials are necessary for monitoring the accuracy of MLH1 protein deficiency assays used in clinical laboratories. METHODS: CRISPR/Cas9 technology was used to edit the MLH1 gene of GM12878Cas9 cells to establish MLH1...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
